RTP Mobile Logo
Oncology Grand Rounds Series: Part 11 — Prostate Cancer (Faculty Presentations)
Released September 2020

Featuring slide presentations and related discussion from Dr Robert Dreicer, Ms Kara M Olivier, Ms Victoria Sinibaldi and Dr Matthew R Smith. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

    OVERVIEW OF ACTIVITY
    Cancers of the genitourinary system affect hundreds of thousands of people in the United States each year and account for more than one fourth of all newly diagnosed human cancer cases. Of this diverse array of distinct diseases, tumors of the prostate are among the most prevalent and are thus the focus of extensive ongoing clinical research. A result of this research is that the clinical management of both early and more advanced presentations of prostate cancer (PC) is constantly evolving, necessitating rapid and consistent access to learning opportunities for nurses who care for these patients. Interprofessional collaboration is increasingly important in the provision of effective care, and prospective and retrospective patient-level research has shown that oncology nurses can play a critical role in the successful delivery of systemic therapy.

    These presentations recorded in advance of and in conjunction with a live CNE webinar symposium originally planned for the 2020 ONS Congress in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development provide the perspectives of a group of leading clinical investigators and nurse practitioners to address some of the most frequently encountered questions and controversies facing clinicians involved in the management of PC and thus to help oncology nurses in the optimal application of newer, more effective options in patient care.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with PC.

    LEARNING OBJECTIVES

    • Apply existing and emerging research data in the therapeutic and supportive care of patients with early and advanced PC.
    • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant PC, and apply this information in the discussion of nonresearch treatment options with patients.
    • Counsel patients with hormone-sensitive metastatic PC regarding the use of cytotoxic and secondary hormonal therapy to ensure appropriate and informed shared decision-making.
    • Recognize how prior therapeutic exposure and patient and disease characteristics factor into the selection and sequencing of available systemic treatments for metastatic castration-resistant PC.
    • Educate patients about the side effects associated with approved therapies commonly employed in the management of advanced PC, and provide preventive strategies to reduce or ameliorate these toxicities.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with PC to optimize clinical and quality-of-life outcomes.

    CONTACT INFORMATION
    If you have questions regarding credit, please contact cpdsupport@usf.edu.

    ACCREDITATION STATEMENT
    USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    A maximum of 3.5 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity.

    This activity is awarded 3.5 ANCC pharmacotherapeutic contact hours.



    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSProstate2020/Presentations/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for CNE (NCPD) accreditation. CNE (NCPD) programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE (NCPD) provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice/ONSProstate2020/Presentations/CNE.

    CONTENT VALIDATION AND DISCLOSURES
    USF Health adheres to ACCME and ANCC standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Robert Dreicer, MD, MS
    Section Head, Medical Oncology
    Deputy Director, University of Virginia Cancer Center
    Associate Director for Clinical Research
    Co-Director, Paul Mellon Urologic Cancer Institute
    Professor of Medicine and Urology
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: Astellas, Eisai Inc, Janssen Biotech Inc, Novartis, Orion Corporation, Pfizer Inc, Seattle Genetics, Vizuri Health Sciences; Contracted Research: Bristol-Myers Squibb Company, Exelexis Inc, Pfizer Inc, Seattle Genetics.

    Kara M Olivier, NP, APRN-BC
    Massachusetts General Hospital Cancer Center
    Claire and John Bertucci Center for Genitourinary Cancers
    Boston, Massachusetts

    No financial interests or affiliations to disclose.

    Victoria Sinibaldi, RN, MS, CS, CANP, BC
    Adult and Geriatric Nurse Practitioner
    Research Associate in Oncology and Urology
    Faculty, School of Medicine, Johns Hopkins University
    Affiliate Staff, Johns Hopkins Hospital
    Baltimore, Maryland

    No financial interests or affiliations to disclose.

    Matthew R Smith, MD, PhD
    Claire and John Bertucci Endowed Chair in Genitourinary Cancers
    Professor of Medicine
    Harvard Medical School
    Director, Genitourinary Malignancies Program
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Janssen Biotech Inc, Lilly.

    COURSE DIRECTOR/PANEL MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    USF HEALTH CPD STAFF, RESEARCH TO PRACTICE CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — No relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Pfizer, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.

    Release date: September 2020
    Expiration date: September 2021

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):